Genomic heterogeneity complicates our ability to accurately diagnosis and treat complex diseases. New technologies help quantify heterogeneity in biological samples, but lead to analytical challenges in translating this data to clinically actionable knowledge.

In cancer, our first area of focus, the heterogeneous nature of the disease is well known but poorly understood. The genomic changes driving these cancers vary within and across patients. This heterogeneity challenges the "one-size-fits-all" treatment paradigm. Further, cancer therapies are becoming more individualized with the emergence of cancer vaccines, immuno-oncology and CAR-T therapies.

Medley Genomics software platform characterizes the unique molecular and cellular landscape within a patient's cancer offering individualized diagnosis and treatment of the tumor ecosystem.

 
 

In the US last year over 1.6M people were diagnosed with cancer. More precise therapies for these cancer patients improve their life expectancies. Yet one in four deaths last year, more than 600,000 people, were the result of cancer, still a deadly disease.

Our understanding of genomic heterogeneity has grown with new science and technologies. By our efforts to describe genomic heterogeneity of a patient’s primary tumor through deconvolution of molecular sequencing data we hope to better inform initial therapeutic decisions, including combination therapies, offering significant benefit in patient outcomes.

medley: a mixture, especially of heterogeneous elements; hodgepodge; jumble